T. Rowe Price Associates
VIR icon

T. Rowe Price Associates’s Vir Biotechnology VIR Stock Holding History

T. Rowe Price Associates’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.32M Buy
129,789
+33,644
+35% +$320K ﹤0.01% 2195
2026
Q1 		$862K Buy
96,145
+14,534
+18% +$116K ﹤0.01% 2228
2025
Q4 		$493K Buy
81,611
+34,475
+73% +$205K ﹤0.01% 2404
2025
Q3 		$270K Buy
47,136
+4,201
+10% +$21.5K ﹤0.01% 2655
2025
Q2 		$217K Sell
42,935
-31,743
-43% -$170K ﹤0.01% 2677
2025
Q1 		$484K Buy
74,678
+3,346
+5% +$29.8K ﹤0.01% 2259
2024
Q4 		$524K Buy
71,332
+3,506
+5% +$27.7K ﹤0.01% 2261
2024
Q3 		$509K Buy
67,826
+9,983
+17% +$86.7K ﹤0.01% 2235
2024
Q2 		$515K Buy
57,843
+4,464
+8% +$42.8K ﹤0.01% 2178
2024
Q1 		$541K Sell
53,379
-33,225
-38% -$338K ﹤0.01% 2178
2023
Q4 		$872K Sell
86,604
-149,323
-63% -$1.36M ﹤0.01% 1933
2023
Q3 		$2.21M Sell
235,927
-566,107
-71% -$8.07M ﹤0.01% 1420
2023
Q2 		$19.7M Buy
802,034
+415,089
+107% +$10.4M ﹤0.01% 941
2023
Q1 		$9.01M Buy
386,945
+1,297
+0.3% +$33.2K ﹤0.01% 1076
2022
Q4 		$9.76M Buy
385,648
+39
+0% +$956 ﹤0.01% 1057
2022
Q3 		$7.44M Buy
385,609
+209,070
+118% +$5.31M ﹤0.01% 1121
2022
Q2 		$4.5M Sell
176,539
-273,824
-61% -$6.39M ﹤0.01% 1435
2022
Q1 		$11.6M Sell
450,363
-147,070
-25% -$4.36M ﹤0.01% 1347
2021
Q4 		$25M Buy
597,433
+560,914
+1,536% +$22M ﹤0.01% 1229
2021
Q3 		$1.59M Sell
36,519
-39,334
-52% -$1.7M ﹤0.01% 1834
2021
Q2 		$3.59M Buy
75,853
+13,874
+22% +$631K ﹤0.01% 1578
2021
Q1 		$3.18M Sell
61,979
-3,437
-5% -$185K ﹤0.01% 1566
2020
Q4 		$1.75M Buy
65,416
+38,960
+147% +$1.27M ﹤0.01% 1689
2020
Q3 		$908K Buy
+26,456
New +$1.14M ﹤0.01% 1839

Other funds holding VIR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

T. Rowe Price Associates's VIR Position: Q2 2026 in Review

T. Rowe Price Associates increased its Vir Biotechnology (VIR) stake by 35% in Q2 2026, buying an estimated $320K and bringing the position to 129,789 shares worth $1.32M. The position accounts for ﹤0.01% of the portfolio, ranked #2195.

T. Rowe Price Associates first reported a position in VIR in Q3 2020 and has held it in 24 quarters since. The position peaked at $25M in Q4 2021. 237 funds tracked by Wall St. Rank hold VIR as of Q2 2026.

  • T. Rowe Price Associates held 129,789 shares of Vir Biotechnology worth $1.32M as of Q2 2026.
  • T. Rowe Price Associates bought 33,644 Vir Biotechnology shares in Q2 2026, an estimated $320K.
  • Vir Biotechnology made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #2195 holding.
  • T. Rowe Price Associates first reported a position in Vir Biotechnology in Q3 2020 and has held it in 24 quarters since.
  • T. Rowe Price Associates's Vir Biotechnology position peaked at $25M in Q4 2021.
  • 237 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.